Clinical Trial Update: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors [Phase 2]

View source ↗

Summary

Telix's phase 2 trial of the CAIX-targeting PET tracer 89Zr-girentuximab in CAIX-positive solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• 89Zr-girentuximab (girentuximab)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Conditions: Cervical Cancer, Colorectal Cancer | Phase 2 | Status: TERMINATED